{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T15:24:43Z","timestamp":1771169083408,"version":"3.50.1"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Patients with spontaneous and traumatic intracranial hemorrhage (ICH) are frequently transfused platelets to treat thrombocytopenia, platelet function defects, and reverse antiplatelet drugs. ABO-identical platelet transfusion has been suggested to lead to higher post-transfusion platelet increments compared to major-ABO incompatible transfusion. We hypothesized that patients who received ABO-identical transfusion would have higher post-transfusion platelet increments and superior neurologic outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Adults with traumatic or non-traumatic ICH from January 1<jats:sup>st<\/jats:sup> 2018 to December 31<jats:sup>st<\/jats:sup> 2022 were identified using electronic medical records and international classification of disease (ICD)-10 codes. Patients were excluded if they lacked a platelet count within 24 hours before and within 24 hours after transfusion or if they received multiple platelet transfusions before their platelet count was remeasured. After stratification by ABO-identical, ABO-major incompatible, and ABO-minor incompatible transfusion, post transfusion increments were compared, as were clinical outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Among 167 patients who received platelet transfusion, 76 (45.5%) received ABO-identical transfusion, 54 (32.3%) received ABO-major incompatible transfusion, and 37 (22.2%) received ABO-minor incompatible transfusion. There were no significant differences in absolute platelet increment between groups. The median increment was 7x10<jats:sup>9<\/jats:sup>\/L for ABO-identical platelets, 10x10<jats:sup>9<\/jats:sup>\/L for ABO-major incompatible platelets, and 11x10<jats:sup>9<\/jats:sup>\/L for ABO-minor incompatible platelets, <jats:italic>p<\/jats:italic> = .87. There was no significant difference in the percentage of patients discharged alive with modified Rankin score of 1 or 2 or cerebral performance category 1 or 2 between groups (<jats:italic>p<\/jats:italic> = .56 and .39 respectively). After adjusting for confounders in a general linear model there remained no associations between ABO compatibility and platelet increment after transfusion.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our data support similar efficacy for ABO-identical and ABO-incompatible platelet transfusion in patients with ICH.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0312602","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T18:49:13Z","timestamp":1732214953000},"page":"e0312602","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["ABO-identical versus incompatible platelet transfusion in patients with intracranial hemorrhage"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4167-2068","authenticated-orcid":true,"given":"Lauren K.","family":"Dunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Venner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Perdomo","family":"Trejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Holley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhiken I.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mazzeffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"issue":"2","key":"pone.0312602.ref001","doi-asserted-by":"crossref","first-page":"E206","DOI":"10.1503\/cjs.018120","article-title":"Routine platelet transfusion in patients with traumatic intracranial hemorrhage taking antiplatelet medication: Is it warranted?","volume":"65","author":"C Wolff","year":"2022","journal-title":"Can J Surg"},{"issue":"2","key":"pone.0312602.ref002","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/STROKEAHA.120.031478","article-title":"Thrombocytopenia and Clinical Outcomes in Intracerebral Hemorrhage: A Retrospective Multicenter Cohort Study","volume":"52","author":"A Mrochen","year":"2021","journal-title":"Stroke"},{"issue":"1","key":"pone.0312602.ref003","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/s41598-020-57683-7","article-title":"Platelet transfusion in patients with aneurysmal subarachnoid hemorrhage is associated with poor clinical outcome","volume":"10","author":"R Post","year":"2020","journal-title":"Sci Rep"},{"key":"pone.0312602.ref004","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.wneu.2020.03.216","article-title":"The Role of Platelet Transfusions After Intracranial Hemorrhage in Patients on Antiplatelet Agents: A Systematic Review and Meta-Analysis","volume":"141","author":"E Brogi","year":"2020","journal-title":"World Neurosurg"},{"issue":"10038","key":"pone.0312602.ref005","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"MI Baharoglu","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"pone.0312602.ref006","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association\/American Stroke Association","volume":"53","author":"SM Greenberg","year":"2022","journal-title":"Stroke"},{"issue":"3","key":"pone.0312602.ref007","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"RM Kaufman","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0312602.ref008","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1182\/hematology.2020000135","article-title":"Does ABO and RhD matching matter for platelet transfusion?","volume":"2020","author":"NM Dunbar","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"pone.0312602.ref009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/0973-6247.162684","article-title":"Current trends in platelet transfusions practice: The role of ABO-RhD and human leukocyte antigen incompatibility","volume":"9","author":"S Valsami","year":"2015","journal-title":"Asian J Transfus Sci"},{"issue":"5","key":"pone.0312602.ref010","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1213\/ANE.0000000000006918","article-title":"Platelet Transfusions: The Good, the Bad, and the Ugly","volume":"138","author":"N Blumberg","year":"2024","journal-title":"Anesth Analg"},{"issue":"10","key":"pone.0312602.ref011","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2003-08-2724","article-title":"Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients","volume":"105","author":"SJ Slichter","year":"2005","journal-title":"Blood"},{"issue":"19","key":"pone.0312602.ref012","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.2020008381","article-title":"Impacts of ABO-incompatible platelet transfusions on platelet recovery and outcomes after intracerebral hemorrhage","volume":"137","author":"J Magid-Bernstein","year":"2021","journal-title":"Blood"},{"issue":"7905","key":"pone.0312602.ref013","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(75)92830-5","article-title":"Assessment of outcome after severe brain damage","volume":"1","author":"B Jennett","year":"1975","journal-title":"Lancet"},{"issue":"5","key":"pone.0312602.ref014","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"JC van Swieten","year":"1988","journal-title":"Stroke"},{"issue":"16","key":"pone.0312602.ref015","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019003298","article-title":"PATCH trial: explanatory analyses","volume":"135","author":"MI Baharoglu","year":"2020","journal-title":"Blood"},{"issue":"3","key":"pone.0312602.ref016","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/emermed-2021-211189","article-title":"Survey evaluating clinical equipoise around platelet transfusion after head injury and traumatic intracranial haemorrhage (ICH) in patients on antiplatelet medications","volume":"39","author":"C Ashton","year":"2022","journal-title":"Emerg Med J"},{"issue":"1","key":"pone.0312602.ref017","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13054-023-04650-z","article-title":"Prophylactic platelet transfusion response in critically ill patients: a prospective multicentre observational study","volume":"27","author":"F Reizine","year":"2023","journal-title":"Crit Care"},{"issue":"5","key":"pone.0312602.ref018","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/trf.15156","article-title":"Isolated platelet concentrate transfusion during surgery: a single-center observational cohort study","volume":"59","author":"M Anders","year":"2019","journal-title":"Transfusion"},{"issue":"9","key":"pone.0312602.ref019","doi-asserted-by":"crossref","first-page":"e2123629","DOI":"10.1001\/jamanetworkopen.2021.23629","article-title":"Recommended Primary Outcomes for Clinical Trials Evaluating Hemostatic Agents in Patients With Intracranial Hemorrhage: A Consensus Statement","volume":"4","author":"SA Mayer","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"pone.0312602.ref020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2018-02-831289","article-title":"Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial","volume":"132","author":"PF van der Meer","year":"2018","journal-title":"Blood"},{"issue":"4","key":"pone.0312602.ref021","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jamaoncol.2017.5123","article-title":"Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients With Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial","volume":"4","author":"F Garban","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"pone.0312602.ref022","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens11060639","article-title":"Efficacy and Safety of Pathogen-Reduced Platelets Compared with Standard Apheresis Platelets: A Systematic Review of RCTs","volume":"11","author":"I Pati","year":"2022","journal-title":"Pathogens"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0312602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T18:49:22Z","timestamp":1732214962000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0312602"}},"subtitle":[],"editor":[{"given":"Heather Faith","family":"Pidcoke","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0312602","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}